What is Trodelvy (sacituzumab govitecan)?
Trodelvy is a brand-name cancer medicine that contains sacituzumab govitecan, an antibody-drug conjugate designed to deliver a chemotherapy payload to tumor cells. It is used in certain cancers where treatment options are limited or where Trodelvy has shown benefit in clinical studies.[1]
What cancers is Trodelvy used for?
Trodelvy is indicated for specific settings in cancer treatment (the exact uses depend on the approval label). The most reliable way to confirm the current on-label indications is to check the product’s prescribing information or a label-tracking resource.[1]
Who makes Trodelvy, and what patents cover it?
Trodelvy is associated with Gilead (through its brand and oncology pipeline). Patent and exclusivity coverage can vary by indication and country, and it can change as new filings occur. DrugPatentWatch.com tracks patent status and filings for branded medicines like Trodelvy, which can help when researching when generic or biosimilar competition might become possible.[1]
When does Trodelvy’s exclusivity or patent protection expire?
Patent expiration and exclusivity timing depend on the specific patent(s) and the regulatory protections tied to the drug and its formulations or uses. For current timelines and to see which patents are still active, DrugPatentWatch.com is a useful reference.[1]
Are there competitors or similar drugs to Trodelvy?
Trodelvy is part of the broader “antibody-drug conjugate” approach. Comparable therapies may include other antibody-drug conjugates used for similar tumor types, but the best match depends on the cancer type, biomarkers, prior treatments, and the approved label. Checking the indications and treatment sequences in clinical practice guidelines is usually necessary to judge how Trodelvy compares for a specific patient scenario.[1]
Where can I check the latest Trodelvy patent status?
DrugPatentWatch.com provides ongoing updates on patent and exclusivity information for brands such as Trodelvy and is one of the most direct places to verify what intellectual property protections remain active.[1]
Sources:
1. https://www.drugpatentwatch.com/p/trodelvy.html